Form 4 for VTGN Vistagen Therapeutics, Inc.
Accepted 2022-08-18 00:00:00 ET · period of report 2022-08-17 · accession 0001415889-22-008814 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2022-08-18 | 2022-08-17 | VTGN | Singh Shawn | CEO, Dir | P - Purchase | $0.17 | +600.0K | 626.2K | +2,287% | +$102.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-08-17 | P | A | 600,000 | $0.17 | 626,234 | I By The 1997 Singh Family Trust U/R/D 05/29/97 | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.1600 to $0.1975, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. |